Epigenetic therapy in allogeneic hematopoietic stem cell transplantation

Qaiser Bashir, Basem Magdy William, Guillermo Garcia-Manero, Marcos de Lima

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

DNA methylation and other epigenetic phenomena appear to be relevant in the pathogenesis of several malignant disorders. DNA methyltransferases add methyl groups to cytosine-phosphate-guanine (CpG) islandsleading to gene promoter silencing. The DNA methyltransferases inhibitors azacitidine and decitabine have anti-tumor activity against a broad range of malignancies, but have been investigated mostly in myelodysplastic syndrome. In addition, these agents have immunomodulatory effects that are under investigation in the allogeneic stem cell transplantation scenario. Both drugs have been used in the perioperative period of allogeneic transplantations with varying degrees of success. It has been hypothesized that low dose azacitidine may increase the graftversus-leukemia effect and have a role in the maintenance of remission after allogeneic transplantation for myeloid leukemias. It is also intriguing that this favorable effect might occur while mitigating graft-versus-host disease. Here we present a review of the rapidly growing field of epigenetic manipulation using hypomethylating agents in allogeneic transplantation.

Original languageEnglish (US)
Pages (from-to)126-133
Number of pages8
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume35
Issue number2
DOIs
StatePublished - 2013

Keywords

  • Azacitidine
  • DNA methyltransferase
  • Epigenesis
  • Genetic
  • Hematopoietic stem cell transplantation
  • Immunologic factors
  • Leukemia
  • Myeloid

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Epigenetic therapy in allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this